

P&T Motion History Statins

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<u>Individual Statins</u> atorvastatin fluvastatin fluvastatin ER lovastatin lovastatin ER pitavastatin pravastatin rosuvastatin simvastatin (oral suspension)	After considering the evidence of safety, efficacy and special populations, I move that the following statins are safe and efficacious: pitavastatin, atorvastatin, fluvastatin, fluvastatin ER, lovastatin, lovastatin ER, pravastatin, rosuvastatin, and simvastatin (all forms) and can be subjected to therapeutic interchange in the Washington Preferred Drug List. The PDL must include at least one high potency option (atorvastatin and/or rosuvastatin) and the PDL must include pravastatin as an alternative with minimal cytochrome P450 drug interactions.	April 19, 2017	Yes Chew Johnson	No	Passed unanimous
<u>Combination Products</u> atorvastatin/ ezetimibe simvastatin/ ezetimibe	I move to not include the combination products as part of the statin drug class on the PDL. Motion: Chew 2 nd . Johnson				

Bold = new this update
 Grey = product is discontinued
 4/20/2017